Parkinson Disease Therapeutics Market 2021 Regional Growth To 2027 By Top Players

Parkinson Disease Therapeutics Market 2021 Regional Growth To 2027 By Top Players

Parkinson’s disease is a neurological disorder that results in patients experiencing difficulties in performing cognitive activities like walking. The symptoms of this disease appear gradually and once this disorder progresses, patients have difficulty in talking and walking. They may also experience sleep problems, behavioral changes, memory difficulties, fatigue and depression. Early forms of Parkinson’s are often inherited and somehow linked to certain genetic mutations.

The awareness about Parkinson’s disease among the population has surged over the years. Also, financial assistance for R&D activities to develop therapeutic infrastructure for Parkinson’s disease has increased. For instance, Parkinson’s Foundation, in 2020, allotted investments of over USD 3.5 million through 34 research grants. These grants help promising scientists to perform extensive researches on Parkinson’s diseases.

Request for a sample copy of this report @  

In addition, Michael. J. Fox Foundation promotes clinical, translational and basic industrial and academic research.  Also, the financial support offered by the Parkinson’s Disease Biomarkers Program helps in identifying the diagnostic and progressive biomarkers for Parkinson’s disease. Such financial initiatives by various organizations will propel industry growth over the forecasted timeframe.

In fact, according to a Global Market Insights Inc. report, the global Parkinson’s disease therapeutics market size is predicted to surpass USD 8 billion by the end of 2027.


Under the drug class segment, dopamine agonist accounted for a substantial market share in 2020 with a valuation of over USD 694 million. This is because Parkinson’s disease causes damage to the brain nerve cells generating dopamine. Also, patients with an early diagnosis of Parkinson’s disease can take long-term treatments with dopamine agonists before shifting to other treatments. This drug imitates the effects of dopamine by forming a bond with the dopamine receptors. It is also less vigorous than levodopa, a dopamine precursor that induces a side effect called dyskinesia.



Brazil Parkinson’s disease therapeutics market accounted for a revenue share of more than USD 90 million in 2020 owing to the increased number of Parkinson’s disease cases in the country.  Also, the government of Brazil has heavily invested in developing advanced infrastructures for research and development activities related to the disease. In fact, the healthcare research policy of Brazil promotes partnerships and networks amongst researchers in academic institutions to maintain the quality of research. 

Request for customization @

The subcutaneous administration route increases the effectivity of dopamine inducing drugs like L-DOPA, dopamine agonists by increasing bioavailability and onset speed. This is one of the factors owing to which the subcutaneous segment is predicted to grow at a CAGR of around 8.1% over the forecasted timeframe. This administration route aids in reducing the possibility of causing dyskinesia. Also, drugs like apomorphine are delivered to patients using the subcutaneous route of administration.

Parkinson’s disease (PD) gets worse with increasing age and hence adults are more prone to getting diagnosed with PD than children. This is the reason the adult patient segment is predicted to proliferate at a CAGR of around 6.9% over the projected timeframe. In addition, there is a surging rise in the geriatric population across the world which has majorly contributed to the segment growth.

Partial Chapter of the Table of Content

Chapter 2   Executive Summary

2.1    Parkinson’s disease therapeutics industry 3600 synopsis, 2016 - 2027 (USD Million)

2.1.1    Business trends

2.1.2    Drug class trends

2.1.3    Route of administration trends

2.1.4    Patient trends

2.1.5    Regional trends

Chapter 3   Parkinson’s Disease Therapeutic Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 - 2027 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers    Growing aging population coupled with increasing prevalence of Parkinson’s disease    Increasing number of drug approvals    Growing awareness among the population    Growing funding in R&D

3.3.2    Industry pitfalls & challenges    High cost of the treatment

3.4    Growth potential analysis

3.4.1    By drug class

3.4.2    By route of administration

3.4.3    By patient

3.5    COVID-19 impact analysis

3.6    Pipeline analysis

3.7    Porter’s analysis

3.8    Competitive landscape, 2019

3.8.1    Competitive matrix analysis

3.9    PESTEL analysis

Browse complete Table of Contents (ToC) of this research report @